Net sales for the first quarter of the fiscal year ending March 2026 were 126.3 billion yen (up 2.9% YoY), operating profit was 3.6 billion yen (down 71.6% YoY), and net income attributable to owners of the parent was 3.4 billion yen (down 62.0% YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4569-20260512-04.pdf","jir_short_summary":"Net sales for the first quarter of the fiscal year ending March 2026 were 126.3 billion yen (up 2.9% YoY), operating profit was 3.6 billion yen (down 71.6% YoY), and net income attributable to owners of the parent was 3.4 billion yen (down 62.0% YoY).","jir_summary":"### Business Performance Overview\nThe consolidated financial results for the first quarter of the fiscal year ending March 2026 show net sales of 126.3 billion yen, an increase of 2.9% from the same period last year. Sales of new pharmaceuticals (domestic) reached 87.1 billion yen (35% increase), new pharmaceuticals (overseas) reached 0.7 billion yen (922% increase), and sales of generic drugs totaled 38.5 billion yen (37% increase). Operating profit declined by 71.6% to 3.6 billion yen, and ordinary income decreased by 69.5% to 4.0 billion yen. Net income attributable to owners of the parent was 3.4 billion yen, down 62.0%. R&D expenses increased by 14.7% to 12.1 billion yen. The increase in selling, general and administrative expenses is a major factor in the profit decline.\n\n### Outlook\nAlthough sales are expected to grow for Beova, Rasuvik, and Mucodyne, overall revenue is projected to decline due to decreases in Desalex sales following the entry of generic competitors. R&D expenses are expected to decrease due to reduced upfront payments and trial costs, but operating profit is forecasted to decline due to drug price revisions and decreased gross profit margin. The cost of sales ratio is expected to rise by about 3 percentage points, while the selling, general, and administrative expense ratio excluding R&D expenses is expected to remain nearly flat.","jir_financial_highlights":"Net Sales: 126.3 billion yen (up 2.9% YoY)\nOperating Profit: 3.6 billion yen (down 71.6% YoY)\nOrdinary Income: 4.0 billion yen (down 69.5% YoY)\nNet Income Attributable to Owners of Parent: 3.4 billion yen (down 62.0% YoY)\nDomestic Sales of New Pharmaceuticals: 87.1 billion yen (up 35% YoY)\nOverseas Sales of New Pharmaceuticals: 0.7 billion yen (up 922% YoY)\nSales of Generic Drugs: 38.5 billion yen (up 37% YoY)\nResearch and Development Expenses: 12.1 billion yen (up 14.7% YoY)","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net sales: 126.3 billion yen (up 2.9% YoY)\nOperating profit: 3.6 billion yen (down 71.6% YoY)\nNet income attributable to owners of the parent: 3.4 billion yen (down 62.0% YoY)","jir_meta_title":"\u3010Kyorin Pharmaceutical\u3011Q1 Financial Results for FY2026 | Net Sales 126.3 Billion Yen (+2.9%)","jir_meta_description":"Kyorin Pharmaceutical reports its Q1 fiscal year ending March 2026 financial results. Net sales reached 126.3 billion yen, up 2.9%, with an operating profit of 3.6 billion yen, down 71.6%. Growth driven by new pharmaceuticals.","jir_og_title":"\u3010Kyorin Pharmaceutical\u3011Q1 Financial Results for FY2026 | Net Sales 126.3 Billion Yen (+2.9%)","jir_og_description":"Kyorin Pharmaceutical's Q1 FY2026 financial results. Net sales increased by 2.9% YoY to 126.3 billion yen. Operating profit declined, but growth in new pharmaceuticals continues.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2025\\\",\\\"Q1 FY2026\\\",\\\"Q1 FY2027 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[1301,1263,1218],\\\"backgroundColor\\\":\\\"#6a7bd1\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Profit Trend (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2025\\\",\\\"Q1 FY2026\\\",\\\"Q1 FY2027 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Profit\\\",\\\"data\\\":[126,36,20],\\\"backgroundColor\\\":\\\"#6a7bd1\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2025\\\",\\\"Q1 FY2026\\\",\\\"Q1 FY2027 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[91,34,15],\\\"backgroundColor\\\":\\\"#6a7bd1\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment-wise Net Sales (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic New Drugs\\\",\\\"Overseas New Drugs\\\",\\\"Genetic Drugs\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Q1 FY2025\\\",\\\"data\\\":[842,89,371],\\\"backgroundColor\\\":\\\"#a3c55f\\\"},{\\\"label\\\":\\\"Q1 FY2026\\\",\\\"data\\\":[871,7,385],\\\"backgroundColor\\\":\\\"#6a7bd1\\\"},{\\\"label\\\":\\\"Q1 FY2027 Forecast\\\",\\\"data\\\":[835,3,379],\\\"backgroundColor\\\":\\\"#f4b183\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"r_and_d_expense_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"R&D Expenses Trend (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2025\\\",\\\"Q1 FY2026\\\",\\\"Q1 FY2027 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Research and Development Expenses\\\",\\\"data\\\":[105,121,93],\\\"borderColor\\\":\\\"#6a7bd1\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48159","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n